Charles Schwab Investment Management Inc Design Therapeutics, Inc. Transaction History
Charles Schwab Investment Management Inc
- $601 Billion
- Q3 2025
A detailed history of Charles Schwab Investment Management Inc transactions in Design Therapeutics, Inc. stock. As of the latest transaction made, Charles Schwab Investment Management Inc holds 247,934 shares of DSGN stock, worth $1.83 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
247,934
Previous 250,949
1.2%
Holding current value
$1.83 Million
Previous $845,000
120.83%
% of portfolio
0.0%
Previous 0.0%
Shares
19 transactions
Others Institutions Holding DSGN
# of Institutions
98Shares Held
34.1MCall Options Held
0Put Options Held
0-
Sr One Capital Management, LP6.53MShares$48.1 Million11.31% of portfolio
-
Logos Global Management LP San Francisco, CA3.66MShares$26.9 Million3.19% of portfolio
-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct3.34MShares$24.6 Million0.05% of portfolio
-
Black Rock Inc. New York, NY2.3MShares$17 Million0.0% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA1.95MShares$14.4 Million0.62% of portfolio
About Design Therapeutics, Inc.
- Ticker DSGN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 55,807,900
- Market Cap $411M
- Description
- Design Therapeutics, Inc. a preclinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of genetic diseases caused by nucleotide repeat expansions. The company's portfolio of products comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ syste...